Abstracts tagged "gout"

Abstract Number: 1653 • ACR Convergence 2024
Osteoarthritis Drives Inflammatory Imprinting of Synovial Fibroblasts, Exacerbating Gouty Arthritis Through m6A Modification of S100A4
ZIYI CHEN¹, Yinghui Hua² and Wenjuan Wang¹, ¹Department of Sports Medicine, Huashan Hospital,Fudan University, Shanghai, Shanghai, China (People's Republic), ²Department of Sports Medicine, Huashan Hospital,Fudan University, Shanghai, China (People's Republic)
Background/Purpose: Patients with osteoarthritis (OA) face an elevated risk of future gouty arthritis (GA). To delineate the underlying cellular and molecular mechanisms of OA-driven gout…
Abstract Number: 2016 • ACR Convergence 2024
Treat to Target in Gout Yields Superior Outcomes Compared to Treat to Avoid Symptoms Approach (results from the Gout TrEatment Strategy Overture Trial)
Anusha Moses¹, Martijn Oude Voshaar¹, Tim L.Th. Jansen² and Mart Van De Laar¹, ¹University of Twente, Enschede, The Netherlands, Enschede, Overijssel, Netherlands, ²1VieCuri Medisch Centrum, Venlo, Netherlands
Background/Purpose: Both the European League Against Rheumatism (EULAR) and the American College for Rheumatology (ACR) state that gout can be effectively managed by reducing sUA…
Abstract Number: 0266 • ACR Convergence 2024
Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol
Dansoa Tabi-Amponsah¹, Lisa Stamp², Anne Horne³, Jill Drake⁴, Sarah Stewart⁵, Gregory Gamble³, Keith Petrie¹ and Nicola Dalbeth³, ¹The University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Auckland University of Technology, Auckland, New Zealand
Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…
Abstract Number: 0900 • ACR Convergence 2024
Association Between Serum Urate, Gout, and Prostatic Cancer in European Male Populations: A Mendelian Randomization Study
Sumanth Chandrupatla¹, Nicholas Sumpter¹, Tony Merriman² and Jasvinder Singh³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Homewood, AL, ³Baylor College of Medicine, Birmingham, AL
Background/Purpose: Gout and serum urate (SU) are associated with prostate cancer risk. Previous Mendelian randomization (MR) studies have shown mixed results on the causal relationship…
Abstract Number: 1092 • ACR Convergence 2024
Chronic Kidney Disease Is Associated with Increased Glucose Uptake-associated Metabolic Activity of Visceral Adipose and Subcutaneous Adipose Tissue in Gout Patients
Shunya Kaneshita¹, Sho Fukui², Soheil Niku³, KWANGHOON LEE⁴, Ernest Belezzuoli³, Robert Terkeltaub⁵ and Monica Guma⁶, ¹UCSD, Miyazu city, Kyoto, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³UCSD, La Jolla, ⁴UCSD, San Diego, CA, ⁵Retired, San Diego, CA, ⁶UCSD, La Jolla, CA
Background/Purpose: Gout, a condition characterized by elevated uric acid levels, is linked to multiple complications, including coronary artery disease, hypertension, and type 2 diabetes mellitus.…
Abstract Number: 1878 • ACR Convergence 2024
The Associations Between Gout and Ischemic Colitis Among Hospitalized Patients: A Retrospective Nationwide Analysis
Nidaa Rasheed¹, Humzah Iqbal², SRIKAR SAMA³ and candice reyes⁴, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³University of California San Francisco Fresno, Fresno, CA, ⁴VACCHCS, Fresno, CA
Background/Purpose: Gout is the most common form of inflammatory arthropathy. It occurs due to urate crystal deposition within the joint space, usually in the setting…
Abstract Number: 2017 • ACR Convergence 2024
Race, Ethnicity, and Rheumatology Care Predict Long-term Urate-Lowering Treatment Persistence Following a Treat-to-Target Intervention in a Large, Multicenter Randomized Trial
Samantha Kohn¹, Harlan Sayles¹, Lindsay Helget¹, Bryant England¹, Punyasha Roul², Joshua Qu¹, Jeff Newcomb¹, Bridget Kramer¹, Michael Duryee¹, Anne Davis-Karim³, Mary Brophy⁴, Ryan Ferguson⁴, Michael Pillinger⁵, Tuhina Neogi⁶, Paul Palevsky⁷, Hongsheng Wu⁴, James O'Dell¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³Veterans Affairs, Albuquerque, NM, ⁴Veterans Affairs, Boston, MA, ⁵New York University Grossman School of Medicine, New York,, NY, ⁶Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁷Veterans Affairs, Pittsburgh, PA
Background/Purpose: Gout management guidelines endorse treat-to-target (T2T) urate lowering therapy (ULT) to achieve and maintain serum urate (sUA) < 6.0 mg/dl. While T2T ULT interventions…
Abstract Number: 0267 • ACR Convergence 2024
IL-17 Participates in the Pathogenesis of Chronic Gouty Arthritis
Hong Di¹, Xinxin Han¹, Yun Zhang² and Xuejun Zeng¹, ¹Peking Union Medical College Hospital, Beijing, China, ²Peking Union Medical College Hospital (CAMS), Beijing, China
Background/Purpose: Chronic gouty arthritis (CGA) is different from acute gouty arthritis (AGA), its main characteristics include repeated or even persistent joint symptoms, tophus and bone destruction.…
Abstract Number: 0907 • ACR Convergence 2024
Association of Rare and Common Genetic Variants in MOCOS with Inadequate Response to Allopurinol
Niamh Fanning¹, Murray Cadzow², Ruth Topless³, Chris Frampton⁴, Nicola Dalbeth⁵, Tony Merriman⁶ and Lisa Stamp⁴, ¹University of Otago, Christchurch, New Zealand, ²University of Otago, Dunedin 9054, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶University of Alabama at Birmingham, Homewood, AL
Background/Purpose: The minor allele of the common rs2231142 (Q141K) ABCG2 variant predicts inadequate response to allopurinol urate lowering therapy (ULT). We hypothesize that additional variants in genes…
Abstract Number: 1093 • ACR Convergence 2024
Risk of Dementia in Patients with Gout: Potential Impact of Survival Bias
Joshua Baker¹, Lindsay Helget², chung-Chou Chang³, Bryant England², Brian Coburn¹, Harlan Sayles², Punyasha Roul⁴ and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pittsburgh, Pittsburgh, PA, ⁴UNMC, Omaha, NE
Background/Purpose: Prior studies reported a lower risk of dementia among patients with gout suggesting that hyperuricemia might play a neuroprotective role. However, risk estimates for…
Abstract Number: 1885 • ACR Convergence 2024
Effect of Physical Activity on Mortality in Rheumatoid Arthritis: A Dose-Response Analysis
Bo Chen¹ and Qibing Xie², ¹Chenbo, Chendu, Sichuan, China, ²Department of Rheumatology and Immunology, Chengdu, Sichuan, China
Background/Purpose: Patients with Rheumatoid arthritis (RA) tend to perform less physical activity compared to the recommended guidelines. The long-term effects of physical activity on mortality…
Abstract Number: 2018 • ACR Convergence 2024
Non-adherence to Urate Lowering Therapy in Gout After 5 Years Is Related to Poor Outcomes – Results from the NOR-Gout Study
Tillmann Uhlig¹, Lars F Karoliussen¹, Joseph Sexton², Sella A. Provan², Espen A. Haavardsholm³, Nicola Dalbeth⁴ and Hilde B Hammer¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: People with gout need to adhere to medication over time to achieve good outcomes. We assessed self-reported adherence to medication with urate lowering therapy…
Abstract Number: 0268 • ACR Convergence 2024
Weight Loss Induced by Anti-obesity Medications and Gout Among Overweight and Obesity Individuals: A Population-based Cohort Study
Jie Wei¹, Yilun Wang², Nicola Dalbeth³, Junqing Xie⁴, Jing Wu⁵, Chao Zeng⁶, Guanghua Lei⁷ and Yuqing Zhang⁸, ¹Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ²Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ³University of Auckland, Auckland, New Zealand, ⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁵Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, China (People's Republic), ⁶Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ⁷Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ⁸Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Weight loss is conditionally recommended for gout management; however, the magnitude of the effect of weight loss on incident gout and recurrent gout flares…
Abstract Number: 0920 • ACR Convergence 2024
TGF-β Activated Kinase 1 Inhibition by Pentagalloyl Glucose Inhibits NLRP3 Inflammasome Formation and Ameliorates MSU-Induced Inflammation
Paul Panipinto¹ and Salahuddin Ahmed², ¹Washington State University College of Pharmaceutical Science and Molecular Medicine, Spokane, WA, ²Washington State University, Spokane, WA
Background/Purpose: Monosodium urate (MSU)-induced inflammation is caused by the deposition of MSU crystals in the joints and periarticular tissues under conditions of hyperuricemia. These deposits…
Abstract Number: 1095 • ACR Convergence 2024
The Incidence of Gout Among Individuals with Hyperuricemia over Time – an Insight from a Nationwide Cohort Study
Shay Brikman¹, Amir Bieber², Liel Serfaty, MA³, Ran Abuhasira, MD, PhD⁴, Nadav Rappoport⁵ and Naomi Schlesinger⁶, ¹Emek Medical Center, Afula, Israel, ²Emek Medical Center, Clalit Health Services, Raanana, Israel, ³Department of Software and Information Systems Engineering, Ben-Gurion University of the Negev, Be'er Sheva, Israel, ⁴Clinical Research Center, Soroka University Medical Center, Be'er Sheva, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶University of Utah, Salt Lake City, UT
Background/Purpose: Hyperuricemia is considered the most important risk factor for developing Gout, the most common adult inflammatory arthritis. Hyperuricemia is defined by a serum urate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].